Dec. 1 at 4:34 PM
🔥
$MRNA gets hit as FDA signals tougher vaccine rules
Moderna is sliding after an FDA memo revealed plans for stricter vaccine-approval requirements.
$MRNA dropped over 4%, with traders worried this could delay key programs like its upcoming flu shot and its flu/COVID combo vaccine.
Analysts are warning that the new safety demands could slow Moderna’s entire pipeline at the worst possible time. The stock is already down 40%+ YTD, and Q3 revenue slipped to
$1.02B with a
$200M loss.
The sell-off isn’t isolated either —
$BNTX,
$NVAX, and
$PCVX all took hits as the FDA shifts toward tighter oversight under HHS Secretary RFK Jr.
With
$MRNA now trading near
$24 and heavy regulatory pressure building, the road ahead just got a lot tougher for Moderna bulls. 💉📉
